Critical Review: Syros Pharmaceuticals (NASDAQ:SYRS) and IMV (OTCMKTS:IMVIQ)

Syros Pharmaceuticals (NASDAQ:SYRS) and IMV (OTCMKTS:IMVIQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Syros Pharmaceuticals and IMV’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
IMV	N/A	N/A	N/A

Risk and Volatility

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, IMV has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Syros Pharmaceuticals and IMV, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0	4	0	0	2.00
IMV	0	0	0	0	0.00

Syros Pharmaceuticals currently has a consensus target price of $1.00, indicating a potential upside of 62,400.00%. Given Syros Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Syros Pharmaceuticals is more favorable than IMV.

Insider & Institutional Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of IMV shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Syros Pharmaceuticals and IMV”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386,000.00	0.11	-$164.57 million	($3.03)	0.00
IMV	$330,000.00	0.00	-$37.99 million	N/A	N/A

IMV has lower revenue, but higher earnings than Syros Pharmaceuticals.

Summary

Syros Pharmaceuticals beats IMV on 6 of the 9 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.